Oxford Technology makes early-stage investments in high-risk science companies near Oxford.
Portfolio
6
companies
Atelerix
Atelerix provides a gel-based system for storing and transporting biological samples at room temperature.
GripAble
GripAble provides digital rehabilitation programmes for neurological and musculoskeletal conditions.
Lightpoint Medical
Lightpoint Medical builds imaging technology to detect cancer during surgery.
Machine Discovery
Machine Discovery develops machine learning technology to accelerate complex simulations and product design.
MitoRx Therapeutics
Developing targeted therapeutics to arrest the progression of degenerative diseases.
Oxford Cancer Analytics
Oxford Cancer Analytics develops blood tests for early cancer detection using proteomics and artificial intelligence.
The investment round was led by BGF and East Innovate to drive commercial adoption of the company simulation platform.
"Machine Discovery is pioneering the use of machine learning to reduce product development cycles in a variety of sectors."
The funding round was led by Eka Ventures and will support international studies and product development.
"Existing data suggests that current approaches fall short at accurately detecting and localizing the deadliest cancers that desperately need to benefit from a blood test. At OXcan, we are using state-of-art and unbiased high-throughput proteomics approaches to examine hundreds and thousands of proteins in blood samples from largest studies of their kind for the first time. Combined with proprietary and tailored machine learning approaches, the results are products that fully integrate with existing care pathways and can detect and localize the deadliest cancers with unprecedented sensitivity and specificity."
Science Angel Syndicate backed the funding round alongside a broad group of institutional and angel investors.
"I've long been fascinated by how reversing mitochondrial dysfunction could arrest the progression of degenerative diseases, which place great burdens on patients and healthcare systems. This seed financing will enable us to advance MitoRx's first-in-class therapeutic pipeline. We are the first biotech to address dysfunction of sulfide-signalling, a fundamental part of life's energy systems. I'm also delighted to welcome Glyn to the team whose wealth of experience will be a great asset as we accelerate our novel pipeline of small molecule mitochondrial protective therapeutics towards the clinic."
The oversubscribed round drew participation from Cancer Research UK, Civilisation Ventures, and various angel investors.
"to shape a future in which early cancer detection becomes the norm rather than the exception"
The financing round was backed by the British Business Bank Future Fund and private investors to accelerate the commercial launch of the SENSEI probe.
